Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks

**OBJECTIVE**
- To evaluate efficacy of baricitinib in eyebrow and eyelash regrowth from baseline through 52 weeks in BRAVE-AA1 and BRAVE-AA2 trials

**CONCLUSIONS**
- The proportion of patients experiencing regrowth of eyebrow and eyelash on baricitinib vs. PBO was statistically significant as early as:
  - Week 4 for eyebrow and Week 8 for eyelash among patients on baricitinib 4-mg
  - Week 8 for eyebrow and eyelash among patients on baricitinib 2-mg
- In the baricitinib 4-mg group, approximately 60% of patients had improvements in eyebrow and eyelash regrowth at Week 36, and this continued to increase to approximately 70% by Week 52
- While baricitinib has demonstrated significant efficacy in regrowth of scalp hair, these data demonstrate the holistic efficacy of baricitinib also in regrowing eyebrows and eyelashes
- These data across multiple timepoints can help inform healthcare practitioners about expectations for eyebrow and eyelash regrowth with baricitinib treatment up to 1 year

**METHODS**
- ClinRO Measures for Eyebrow and Eyelash Hair Loss:
  - ClinRO Measure for Eyebrow Hair Loss
    - Score 0: Full coverage and no areas of hair loss
    - Score 1: Minor gaps or uneven distribution
    - Score 2: Significant gaps or uneven distribution
    - Score 3: No notable eyebrow hair
  - ClinRO Measure for Eyelash Hair Loss
    - Score 0: Continuous line along the eyelids on both eyes
    - Score 1: Minor gaps or uneven distribution along the eyelids on both eyes
    - Score 2: Significant gaps or uneven distribution along the eyelids
    - Score 3: No notable eyelashes
  - A 1-point improvement in ClinRO eyebrow and eyelash indicates early appreciable improvement in eyebrow and eyelash regrowth

**RESULTS**
- Proportion of patients who achieved improvement in eyebrow regrowth
- Proportion of patients who achieved improvement in eyelash regrowth

**SUMMARY OF KEY FINDINGS**
- The proportions of patients reporting eyebrow and eyelash regrowth continued to increase through Week 52 with SBM 6-mg and SBM 4-mg
- Higher response rates were observed with the 4-mg dose vs. the 2-mg dose on all timepoints

**REFERENCES**